GTC Gets an Udder Chance

Investors toasted and torpedoed a plan to extract drugs from the milk of bio-engineered goats. Now, thanks to an EU finding, the stock rise again

The saga of Sweetheart the goat and her creator, GTC Biotherapeutics (GTCB), has seen more highs and lows than the average soap opera. June 2 marked a welcome high for the Framingham (Mass.)-based biotech. The European Medicines Agency issued a positive opinion on the company's drug, ATryn, which is the first drug derived from the milk of a genetically modified animal.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.